Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Jpn J Clin Oncol ; 50(1): 36-43, 2020 Jan 24.
Article in English | MEDLINE | ID: mdl-31665483

ABSTRACT

BACKGROUNDS: The incidence of acute kidney injury and the association between acute kidney injury and prognosis have been reported about transcatheter arterial chemoembolization using anthracycline. However, the incidence of acute kidney injury after platinum-based transarterial chemoembolization or transarterial infusion chemotherapy remains unclear. The aim of this study was to investigate association between acute kidney injury after platinum-based transcatheter arterial chemoembolization/transarterial infusion chemotherapy and prognosis in patients with hepatocellular carcinoma. METHODS: We retrospectively analysed 270 sessions in 129 patients who underwent platinum-based transcatheter arterial chemoembolization/transarterial infusion chemotherapy. Acute kidney injury was diagnosed according to the criteria established by the International Club of Ascites. The incidence of acute kidney injury, risk factors for serum creatinine elevation and association between acute kidney injury and prognosis were assessed. RESULTS: Fifteen cases of acute kidney injury (5.6%, 15/270) developed in 14 patients (10.8%, 14/129). Ascites (coefficient: 0.059, P = 0.006), low estimated glomerular filtration rate (coefficient: -0.008, P = 0.029), diabetes (coefficient: 0.072, P < 0.001) and high albumin-bilirubin grade (albumin-bilirubin grade 2: coefficient: 0.053, P = 0.004; and albumin-bilirubin grade 3: coefficient: 0.103, P < 0.001) were significantly associated with an elevation in serum creatinine levels after transcatheter arterial chemoembolization/transarterial infusion chemotherapy. The development of acute kidney injury was associated with poor prognosis (hazard ratio: 3.18, 95%CI: 1.411-7.171, P = 0.005). Patients with acute kidney injury had a significantly lower survival rate than patients without acute kidney injury (log-rank test; P = 0.034). CONCLUSIONS: The incidence of acute kidney injury after platinum-based transcatheter arterial chemoembolization/transarterial infusion chemotherapy was consistent with that after transcatheter arterial chemoembolization using anthracycline, and the development of acute kidney injury was associated with poor prognosis. Ascites, diabetes, low estimated glomerular filtration rate and high albumin-bilirubin grade were risk factors for serum creatinine elevation after platinum-based transcatheter arterial chemoembolization/transarterial infusion chemotherapy.


Subject(s)
Acute Kidney Injury/epidemiology , Carcinoma, Hepatocellular/drug therapy , Chemoembolization, Therapeutic/adverse effects , Chemotherapy, Cancer, Regional Perfusion/adverse effects , Liver Neoplasms/drug therapy , Platinum/therapeutic use , Aged , Antibiotics, Antineoplastic/therapeutic use , Ascites/pathology , Bilirubin/blood , Carcinoma, Hepatocellular/pathology , Diabetes Mellitus/pathology , Female , Glomerular Filtration Rate/physiology , Humans , Incidence , Liver Neoplasms/pathology , Male , Prognosis , Retrospective Studies , Risk Factors , Serum Albumin, Human , Survival Rate , Treatment Outcome
2.
Hepatol Res ; 49(7): 778-786, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30884044

ABSTRACT

AIM: Sarcopenia has a negative impact on the prognosis of patients with hepatocellular carcinoma (HCC). We investigated the significance of skeletal muscle volume and its changes in HCC patients receiving transarterial chemoembolization (TACE). METHODS: We retrospectively analyzed 179 HCC patients receiving TACE from 2006 to 2017. Skeletal mass index was calculated as the left-right sum of the major × minor axis of the psoas muscle at the third lumbar vertebra, divided by height squared (psoas muscle index [PMI]). Patients were classified into two groups (low and normal PMI) depending on an index <6.0 and <3.4 cm2 /m2 for men and women, respectively. We assessed overall survival (OS) and TACE period (between the first TACE [Pre] and the time of TACE refractoriness [Post]). Changes in PMI per month during the TACE period (CPMI; (PMI [Pre] - PMI [Post]) / TACE period) were calculated as an index of progressive muscle atrophy. RESULTS: There were no significant differences in OS between groups with low and normal PMI at Pre. Multivariate analysis showed that CPMI was significantly associated with poor OS (hazard ratio, 1.884; P = 0.001). Patients with severe muscle atrophy (CPMI above the upper quartile) had a significantly lower OS than those with mild muscle atrophy (CPMI below the upper quartile). Compared with patients with mild muscle atrophy, patients with severe muscle atrophy had a significant loss of liver function reserves at Post. CONCLUSION: Progressive loss of skeletal muscle volume is an important predictor of poor prognosis in HCC patients treated with TACE.

3.
Hepatol Res ; 49(4): 385-393, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30471232

ABSTRACT

AIMS: A non-invasive biomarker for patients with primary biliary cholangitis (PBC) is needed. The association between leucine-rich α2 glycoprotein (LRG) and PBC has not been investigated. We aimed to assess the predictive value of LRG for the development of cirrhosis-related conditions in PBC. METHODS: We retrospectively reviewed clinical data of 129 individuals with biopsy-confirmed PBC. Leucine-rich α2 glycoprotein was analyzed by enzyme-linked immunosorbent assays using stored sera at biopsy (n = 129) and after treatment (n = 80). RESULTS: Levels of LRG decreased significantly after treatment (55.8 µg/mL vs. 39.8 µg/mL, P < 0.001). Neither LRG nor delta-LRG was associated with transaminase or histological findings. Delta-LRG >0 (hazard ratio [HR] 4.61, P = 0.013), delta-LRG >0 and an aspartate aminotransferase/platelet ratio index (APRI) >0.76 (HR 458, P < 0.001) were associated with the development of a cirrhosis-related condition. Patients with a delta-LRG >0 and an APRI >0.76 had a significantly increased rate of developing cirrhosis-related conditions (P < 0.001). CONCLUSIONS: Changes in LRG levels after treatment predicted PBC prognosis but were not associated with histological stage. Changes in LRG in addition to the APRI could be a useful combination of tools for clinicians as a non-invasive biomarker.

4.
Hepatol Res ; 48(11): 893-904, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29734510

ABSTRACT

AIM: Sarcopenia and osteoporosis are important complications in chronic liver disease (CLD). The aim of this study was to investigate the relationship between sarcopenia and osteoporosis in patients with CLD. METHODS: We retrospectively investigated the relationship between sarcopenia and osteoporosis in 112 CLD patients (57 men and 55 women), including 40 cirrhotic patients (36%), by measuring the appendicular skeletal muscle mass index (ASMI) using bio-impedance analysis. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. RESULTS: The sarcopenia rate was 13% (14/112), and the osteoporosis and osteopenia rates were 17% (19/112) and 65% (73/112), respectively. The rate of osteoporosis was significant and high in patients with sarcopenia or cirrhosis. In linear regression analysis, sarcopenia was significantly associated with the BMD of the lumbar spine (coefficient = -0.149, P = 0.014) and the femur neck (coefficient = -0.110, P = 0.003). Cirrhosis was also significantly associated with low BMD of the lumbar spine (coefficient = -0.160, P < 0.001) and the femur neck (coefficient = -0.066, P = 0.015). In the logistic analysis, sarcopenia (odds ratio = 6.16, P = 0.039) and cirrhosis (odds ratio = 15.8, P = 0.002) were independent risk factors for osteoporosis. The ASMI cut-off values for osteoporosis were 7.33 kg/m2 in men and 5.71 kg/m2 in women. CONCLUSIONS: Sarcopenia was closely associated with osteoporosis, and a low ASMI was a potential predictor of osteoporosis in CLD patients. Screening for BMD might be required to detect osteoporosis in cirrhotic patients.

5.
J Gastroenterol Hepatol ; 33(3): 733-740, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28834565

ABSTRACT

OBJECTIVE: This study aimed to evaluate the utility of magnetic resonance elastography (MRE) as a non-invasive method for predicting ascites in patients with chronic liver disease (CLD). METHODS: A total of 208 CLD patients underwent MRE to measure liver stiffness (LS) at our institution from March 2013 to June 2015. We evaluated the diagnostic performance of MRE for predicting the presence of ascites using receiver-operating characteristic (ROC) curve analysis and compared the performance with that of serum fibrosis markers. Multivariate logistic regression analysis was performed to identify factors associated with the presence of ascites. The cumulative incidence of ascites was examined in patients without ascites at baseline. The pathological stage of liver fibrosis was evaluated in 81 CLD patients using histopathologic diagnosis. RESULTS: Of the 208 patients, 41 had ascites. The optimal cut-off LS value for the presence of ascites was 6.0 kPa (area under the ROC curve = 0.87). The area under the ROC curve for the presence of ascites was significantly higher for MRE than that for fibrosis markers. Multivariate analysis revealed that LS >6.0 kPa is an independent risk factor for the presence of ascites. The cumulative incidence of ascites was significantly higher among those with LS values >6.0 kPa. There was significantly greater diagnostic accuracy for liver fibrosis stage ≥4 with MRE than that with fibrosis markers. CONCLUSIONS: Compared with serum fibrosis markers, MRE has higher diagnostic performance in predicting the presence of ascites. MRE-based LS has the potential to predict the presence of ascites in CLD patients.


Subject(s)
Ascites/diagnostic imaging , Ascites/etiology , Elasticity Imaging Techniques , Liver Diseases/complications , Liver Diseases/diagnostic imaging , Liver/diagnostic imaging , Aged , Ascites/epidemiology , Chronic Disease , Elasticity , Female , Fibrosis , Humans , Incidence , Liver/pathology , Liver/physiopathology , Liver Diseases/pathology , Liver Diseases/physiopathology , Logistic Models , Male , Middle Aged , Predictive Value of Tests , ROC Curve , Risk Factors , Sensitivity and Specificity
6.
Med Mol Morphol ; 51(3): 176-185, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29380060

ABSTRACT

Non-invasive predictors for the development of cirrhosis-related conditions are needed for patients with primary biliary cholangitis (PBC). We investigated the association between cytokeratin-18 fragments (M30 and M65) and liver histology, treatment response and the development of cirrhosis-related conditions in patients with PBC. We retrospectively reviewed the clinical data of 111 individuals with biopsy-proven PBC. Serum M30 and M65 levels were measured using stored sera. M30 were significantly decreased after treatment, but there was no significant change in the M65 levels. M65 was significantly higher in non-responders according to the Paris-I and Paris-II definitions. In the multivariate analysis, high levels of M65 were significantly associated with advanced Scheuer stage (odds ratio 5.86; 95% confidence interval 0.55-22.2; P = 0.009) and with the development of cirrhosis-related conditions (hazard ratio 3.94; 95% confidence interval: 1.06-14.5, P = 0.039). Among PBC patients without cirrhosis, those with high serum M65 levels at baseline were at higher risk of developing cirrhosis-related conditions (log-rank test; P = 0.001). High levels of serum M65 may be a non-invasive and early predictor of the development of cirrhosis-related conditions in PBC patients. Our findings may help initiate therapies earlier for those at risk for cirrhosis.


Subject(s)
Biomarkers/blood , Cholagogues and Choleretics/therapeutic use , Cholangitis, Sclerosing/blood , Keratin-18/blood , Liver Cirrhosis, Biliary/epidemiology , Peptide Fragments/blood , Biopsy , Cell Death , Cholangitis, Sclerosing/complications , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/mortality , Female , Follow-Up Studies , Humans , Liver/pathology , Liver Cirrhosis, Biliary/etiology , Liver Cirrhosis, Biliary/prevention & control , Male , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome , Ursodeoxycholic Acid/therapeutic use
7.
Hepatol Res ; 47(3): E55-E63, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27062374

ABSTRACT

AIM: Psychiatric side-effects are the main reason for discontinuation of interferon (IFN)-based therapy. Recent developments in near-infrared spectroscopy (NIRS) have enabled non-invasive clarification of brain functions in psychiatric disorders. We prospectively evaluated brain activation in 20 chronic hepatitis C patients with or without IFN-based therapy by using NIRS during a verbal fluency task (VFT). METHODS: The relative concentrations of oxygenated hemoglobin were measured while patients completed a questionnaire survey at the start of treatment and at 4 and 12 weeks during treatment, using NIRS. RESULTS: The VFT performance did not change among the two groups. Patients with IFN-based therapy showed significantly lower activation during VFT in frontal channels at 12 weeks than those at the start of treatment and control (P < 0.05). Their Center for Epidemiologic Studies Depression Scale scores were significantly higher at 12 weeks than those at the start of treatment, although major depressive symptoms were not found (8.3 ± 7.9 vs. 13.2 ± 6.0, P < 0.001). CONCLUSION: The decrease in oxygenated hemoglobin concentrations of the frontal lobe detected using NIRS in this study reflects hypofunction of the frontal lobe. This functional decline that was caused by IFN-based therapy may be associated with the prodromal phase of depression.

8.
Nihon Shokakibyo Gakkai Zasshi ; 113(5): 821-7, 2016 05.
Article in Japanese | MEDLINE | ID: mdl-27151479

ABSTRACT

A 43-year-old man was admitted to our hospital because of an abnormal shadow on chest X-ray. Blood testing showed elevated levels of C-reactive protein and white blood cells. Computed tomography revealed multilocular masses of the right hepatic lobe, reticulonodular shadowing on both lungs, left kidney masses, and aortic arch aneurysm. Fusobacterium nucleatum was isolated from the hepatic abscess after percutaneous transhepatic drainage. Because of severe dental caries, he was diagnosed with liver abscess caused by dental infection with F. nucleatum. Administration of cefmetazole and meropenem was not effective; however, he showed remarkable improvement after treatment with metronidazole and continuous drainage.


Subject(s)
Fusobacterium Infections/complications , Liver Abscess/etiology , Adult , Anti-Infective Agents/therapeutic use , Drainage , Fusobacterium Infections/therapy , Humans , Liver Abscess/therapy , Male , Metronidazole/therapeutic use
9.
Transfus Apher Sci ; 52(2): 204-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25863413

ABSTRACT

CASE REPORT: We describe a hemodialysis (HD) patient who successfully underwent total hip arthroplasty with autologous blood transfusion (ABT). There were several problems with collecting ABT in this setting. DISCUSSION: A literature search for HD patients and ABT produced 8 articles describing 29 patients. Higher doses of erythropoietin stimulating agents were used to collect ABT than for a typical HD session. In 75% of the cases autologous blood was collected just after HD to collect better quality blood. The optimal clinical procedures for ABT in HD patients need to be clarified.


Subject(s)
Arthroplasty, Replacement, Hip/methods , Blood Transfusion, Autologous/methods , Renal Dialysis/methods , Adolescent , Adult , Aged , Diabetic Nephropathies/complications , Diabetic Nephropathies/therapy , Erythropoietin/therapeutic use , Female , Humans , Male , Middle Aged , Treatment Outcome , Young Adult
10.
Nihon Shokakibyo Gakkai Zasshi ; 112(1): 115-22, 2015 Jan.
Article in Japanese | MEDLINE | ID: mdl-25744928

ABSTRACT

In 1998, a 68-year-old woman was diagnosed with rheumatoid arthritis. She was treated with prednisolone, nonsteroidal anti-inflammatory drugs, methotrexate (MTX), and biological drugs. Retroperitoneal lymph node swelling and hepatosplenomegaly appeared but spontaneously disappeared after drug withdrawal. Anorexia and general fatigue occurred in March 2012. She was admitted to our hospital with retroperitoneal, periaortic, and mediastinal lymph node swelling and was found to have multiple liver tumors. Based on the results of aspiration biopsy of a liver tumor, she was diagnosed with malignant lymphoma (Hodgkin lymphoma). She died from liver failure and disseminated intravascular coagulation before chemotherapy. We present this case of MTX-associated lymphoproliferative disorder, which caused formation of a liver tumor.


Subject(s)
Antirheumatic Agents/adverse effects , Liver/pathology , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/pathology , Methotrexate/adverse effects , Aged , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biopsy , Fatal Outcome , Female , Humans , Methotrexate/therapeutic use
11.
Med Mol Morphol ; 47(3): 162-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24969678

ABSTRACT

Primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) present with distinct clinical features. The term "PBC-AIH overlap syndrome (OS)" has been adopted to describe the condition characterized by occurrence of both PBC and AIH, although this clinical entity is difficult to define. This study aimed to assess the utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of AIH, PBC, and OS. Immunohistochemistry was performed with anti-human IgG, IgM, and CD138 to detect specific plasma cells in the liver. Predominant IgG staining was observed in AIH (85.7 %), while equivocal (46.1 %) or predominant (38.5 %) IgM staining was observed in PBC. In OS, equivocal (20 %) or predominant (80 %) IgG staining was observed. The IgM/IgG ratio was significantly higher in PBC than in AIH or OS (P < 0.005). Histological findings revealed significantly higher IgM expression in PBC at cholangitis activity grades 2-3 compared to those at cholangitis activity grades 0-1. In contrast, a significantly higher IgG expression was observed in PBC at hepatitis activity and fibrosis grades 2-3 compared to those at hepatitis activity and fibrosis grades 0-1. Taken together, periportal plasmacytic infiltrates with variable immunohistochemistry patterns of IgG and IgM expression characterized different autoimmune liver diseases.


Subject(s)
Hepatitis, Autoimmune/diagnosis , Immunoglobulin G , Immunoglobulin M , Liver Cirrhosis, Biliary/diagnosis , Syndecan-1 , Age Factors , Alkaline Phosphatase/blood , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique, Indirect , Histological Techniques , Humans , Immunohistochemistry/methods , Male , Sex Factors , Statistics, Nonparametric , Syndrome , gamma-Glutamyltransferase/blood
12.
Hepatol Res ; 43(9): 984-90, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23675841

ABSTRACT

We report a case of idiopathic portal hypertension (IPH) complicated with autoimmune hepatitis. A 60-year-old woman was admitted to our hospital with esophageal and gastric varices in February 2010. Abdominal ultrasonography and computed tomography showed splenomegaly and collateral veins without evidence of liver cirrhosis. Laboratory examinations and liver biopsy indicated that the esophageal and gastric varices were caused by IPH. She underwent endoscopic injection sclerotherapy and partial splenic embolization. Two years after these therapies, laboratory examinations showed liver dysfunction with elevated levels of aspartate aminotransferase (180 IU/L), alanine aminotransferase (190 IU/L), γ-glutamyl transpeptidase (159 IU/L) and immunoglobulin G (2609 mg/dL). The titer of antinuclear antibodies was 1:320 and its pattern was homogeneous and speckled. Histological examination revealed plasma cell/lymphocyte infiltration and interface hepatitis in the portal tract. Based on these findings, a diagnosis of autoimmune hepatitis accompanied by IPH was made. After treatment with prednisolone (20 mg/day), liver functions were normalized immediately. Overlapping of IPH and AIH is extremely rare, but the present case is interesting considering the etiology of IPH because an autoimmune mechanism is thought to be involved in the pathogenesis of IPH.

13.
Medicine (Baltimore) ; 99(22): e20399, 2020 May 29.
Article in English | MEDLINE | ID: mdl-32481431

ABSTRACT

Cytokeratin 18 (CK18) and fibroblast growth factor 21 (FGF21) are elevated in patients with nonalcoholic fatty liver disease (NAFLD) and are useful markers for identifying or monitoring outcomes. Exercise therapy is one of the established treatments for NAFLD; however, few studies have investigated the effectiveness of exercise therapy on CK18 and FGF21 levels. Therefore, the aim of the present study was to assess the effects of 12 weeks of simple resistance exercise on CK18 and FGF21 levels in patients with NAFLD.Fifty patients with NAFLD were assigned to a resistance exercise group (n = 23) or a control group (n = 27) for a trial period of 12 weeks. During the study, the resistance exercise group performed two exercises (push-ups and squats) three times a week on nonconsecutive days, whereas the control group proceeded with regular physical activities under a restricted diet. We then compared serum levels of CK18 fragments (M65) and FGF21 between groups just before and after the 12-week period.Serum M65 levels (880.0 ±â€Š503.6 vs 648.9 ±â€Š450.2 U/L; P < .01) were significantly decreased in the exercise group. However, no significant differences were observed in body mass index or skeletal muscle. The decreases in serum M65 (-231.1 ±â€Š354.7 vs 56.2 ±â€Š375.0 U/L; P = .02), and FGF21 levels (-41.7 ±â€Š98.2 vs. 33.2 ±â€Š127.6 pg/mL; P = .03) were significantly greater in the exercise than in the control group. Changes in M65 levels in the exercise group were significantly correlated with changes in alanine aminotransferase levels (r = 0.618, P < .01).Simple resistance exercise reduced CK18 and FGF21 levels in patients with NAFLD. These findings suggest that resistance exercise consisting of push-ups and squats helps prevent the progression of NAFLD.


Subject(s)
Fibroblast Growth Factors/blood , Keratin-18/blood , Non-alcoholic Fatty Liver Disease/therapy , Resistance Training/methods , Female , Humans , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/metabolism , Retrospective Studies
14.
Fukushima J Med Sci ; 65(3): 71-75, 2020 Jan 09.
Article in English | MEDLINE | ID: mdl-31564673

ABSTRACT

The gut microbiota plays a key role in the development of chronic inflammatory liver disease. The gut-liver axis involves inflammatory cells, cytokines, and other molecules that cause liver deterioration. Dysbiosis is important in understanding several liver diseases, especially in relation to the development of autoimmune liver disease. The aim of this review is to provide a current overview of alterations in the gut and oral microbiota associated with autoimmune liver diseases.


Subject(s)
Gastrointestinal Microbiome/physiology , Hepatitis, Autoimmune/etiology , Liver Cirrhosis, Biliary/etiology , Mouth/microbiology , Dysbiosis , Hepatitis, Autoimmune/microbiology , Humans , Liver Cirrhosis, Biliary/microbiology
15.
Intern Med ; 58(3): 375-380, 2019 Feb 01.
Article in English | MEDLINE | ID: mdl-30210131

ABSTRACT

Hepatitis B virus (HBV) reactivation occasionally occurs long after immunosuppressive therapy. The characteristics of late HBV reactivation remain unclear. We herein present a case of HBV reactivation in a patient with nonalcoholic steatohepatitis (NASH) more than 3 years after rituximab-containing chemotherapy for diffuse large B-cell lymphoma. Increased transaminase levels, which were induced by NASH, were observed after chemotherapy and were alleviated with statin treatment. HBV reactivation was identified incidentally. The patient developed hepatitis that improved with entecavir therapy. Our case might indicate that the presence of NASH is associated with HBV reactivation long after treatment and that statins, as immune-modulatory agents, affect HBV reactivation.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Antiviral Agents/therapeutic use , Guanine/analogs & derivatives , Hepatitis B/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Rituximab/therapeutic use , Aged, 80 and over , Guanine/therapeutic use , Hepatitis B Surface Antigens/drug effects , Hepatitis B virus/drug effects , Humans , Male , Risk Factors , Treatment Outcome , Virus Activation/drug effects
16.
Hepatol Commun ; 3(5): 670-684, 2019 May.
Article in English | MEDLINE | ID: mdl-31061955

ABSTRACT

Interleukin (IL)-33 was recently described as a new member of the IL-1 family; members of this family have proinflammatory activity. IL-33 and its soluble receptor ST2 (sST2) have been implicated in the pathogenesis of autoimmune diseases. This study investigated serum IL-33 and sST2 in type I autoimmune hepatitis (AIH) and the relationship of these molecules with clinical and pathologic parameters. Subjects included 65 patients with AIH who were diagnosed in our hospital. The control population included 17 healthy individuals and 36 patients with primary biliary cholangitis (PBC). Mean age at AIH diagnosis was 55.5 years, and the male-to-female ratio was 6:59. Serum IL-33 and sST2 levels were significantly higher in patients with AIH than in those with PBC or controls. Importantly, immunohistochemistry revealed high IL-33 expression in liver sections from patients with AIH. In particular, serum IL-33 and sST2 levels were significantly higher in acute-onset AIH than in chronic-onset AIH. Serum IL-33 levels were positively correlated with serum total bilirubin (TB), alanine aminotransferase (ALT), and necroinflammatory activity in AIH. We performed multivariate logistic regression analysis and found serum IL-33 levels to be independent factors for severe activity. Serum sST2 levels were positively correlated with serum TB and ALT and negatively correlated with serum albumin and prothrombin time in AIH. In particular, serum sST2 levels were significantly higher in severe symptoms of AIH. Serum IL-33 and sST2 levels in patients with AIH responsive to treatment with prednisolone were significantly decreased after treatment. Interestingly, serum IL-33 level was associated with a significantly increased risk of relapse. Conclusion: IL-33/ST2 may play an important role in the pathogenesis and severity of AIH and may be a promising target for AIH therapy.

17.
Intern Med ; 58(17): 2507-2514, 2019 Sep 01.
Article in English | MEDLINE | ID: mdl-31118392

ABSTRACT

We report 2 cases of endogenous endophthalmitis associated with pyogenic liver abscess caused by Klebsiella pneumoniae. Case 1 involved a 70-year-old woman and case 2 involved a 50-year-old man who were admitted to our hospital with diagnoses of liver abscess and endogenous endophthalmitis, respectively. The liver abscess resolved with antibiotics and percutaneous transhepatic drainage in case 1 and with antibiotics alone in case 2. Even though both cases underwent ophthalmic surgery, they were discharged from our hospital without the recovery of their eyesight. An earlier diagnosis and treatment are needed to improve the prognosis of endophthalmitis.


Subject(s)
Endophthalmitis/microbiology , Klebsiella Infections/diagnosis , Klebsiella pneumoniae , Liver Abscess, Pyogenic/microbiology , Aged , Anti-Bacterial Agents/therapeutic use , Drainage , Endophthalmitis/complications , Endophthalmitis/diagnosis , Endophthalmitis/therapy , Female , Humans , Klebsiella Infections/drug therapy , Liver Abscess, Pyogenic/complications , Liver Abscess, Pyogenic/diagnosis , Liver Abscess, Pyogenic/therapy , Male , Middle Aged , Prognosis , Vision Disorders/etiology
18.
Intern Med ; 58(8): 1103-1110, 2019 Apr 15.
Article in English | MEDLINE | ID: mdl-30626806

ABSTRACT

We performed split drug-eluting bead transarterial chemoembolization (DEB-TACE) in a patient with huge unresectable hepatocellular carcinoma and multiple intrahepatic metastases. However, TACE was discontinued at the fourth application because the tumor was fed by the cholecystic artery. As most intrahepatic metastases disappeared following DEB-TACE, the patient was able to undergo radical hepatectomy, and has maintained a complete response. DEB-TACE enables cancer treatment without reducing the liver or renal function. However, it is associated with a risk of ischemia in other organs in patients whose arteries feed both tumors and other organs; thus appropriate selection is required.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/surgery , Chemoembolization, Therapeutic/methods , Doxorubicin/therapeutic use , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Carcinoma, Hepatocellular/pathology , Hepatectomy/methods , Hepatic Artery/pathology , Humans , Japan , Liver Neoplasms/pathology , Male , Microspheres , Middle Aged , Treatment Outcome , Vascular Surgical Procedures/methods
19.
Intern Med ; 57(17): 2451-2458, 2018 Sep 01.
Article in English | MEDLINE | ID: mdl-29607963

ABSTRACT

Objective Hyponatremia is closely associated with the pathophysiology of cirrhosis. However, the association between the serum sodium level and the response to tolvaptan is unclear. This study evaluated the factors related to the tolvaptan response and the prognosis in cirrhosis patients with ascites and hyponatremia. Methods We retrospectively reviewed the clinical records of cirrhosis patients hospitalized for treatment with tolvaptan. The associations of patient baseline characteristics with the tolvaptan response after one week and of the characteristics after one-month tolvaptan treatment with the prognosis were analyzed. Results We analyzed 83 cirrhosis patients with ascites, including 34 patients with hyponatremia. The response rates to tolvaptan in patients with serum sodium <130 mEq/L, 130-135 mEq/L, and >135 mEq/L were 20%, 66%, and 58%, respectively (p=0.22). The serum sodium level was associated with the response to tolvaptan [odds ratio=1.18; 95% confidence interval (CI) =1.02-1.37; p=0.029]. In patients with hyponatremia, the serum sodium level after 1-month tolvaptan treatment was increased compared to baseline (132 mEq/L vs. 136 mEq/L, p=0.006), and an increasing serum sodium level was associated with a lower risk of mortality (hazard ratio=0.85; 95% CI=0.75-0.97; p=0.016). The survival rate was higher in patients with an increase in the serum sodium level after 1 month than in patients with a decreased serum sodium level (p=0.023). Conclusion Tolvaptan treatment was effective in cirrhosis patients with ascites and hyponatremia, but a low serum sodium level was associated with non-responsiveness to tolvaptan. An increased serum sodium level after one-month tolvaptan treatment may positively influence the mortality risk in cirrhosis patients with hyponatremia.


Subject(s)
Antidiuretic Hormone Receptor Antagonists/therapeutic use , Ascites/complications , Benzazepines/therapeutic use , Hyponatremia/drug therapy , Liver Cirrhosis/complications , Sodium/blood , Ascites/blood , Female , Humans , Hyponatremia/blood , Hyponatremia/etiology , Liver Cirrhosis/blood , Liver Cirrhosis/mortality , Male , Middle Aged , Prognosis , Retrospective Studies , Tolvaptan , Treatment Outcome
20.
PLoS One ; 13(7): e0198757, 2018.
Article in English | MEDLINE | ID: mdl-29969462

ABSTRACT

The gut microbiota has recently been recognized to play a role in the pathogenesis of autoimmune liver disease (AILD), mainly primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). This study aimed to analyze and compare the composition of the oral microbiota of 56 patients with AILD and 15 healthy controls (HCs) and to evaluate its association with salivary immunological biomarkers and gut microbiota. The subjects included 39 patients with PBC and 17 patients with AIH diagnosed at our hospital. The control population comprised 15 matched HCs. Salivary and fecal samples were collected for analysis of the microbiome by terminal restriction fragment length polymorphism of 16S rDNA. Correlations between immunological biomarkers measured by Bio-Plex assay (Bio-Rad) and the oral microbiomes of patients with PBC and AIH were assessed. Patients with AIH showed a significant increase in Veillonella with a concurrent decrease in Streptococcus in the oral microbiota compared with the HCs. Patients with PBC showed significant increases in Eubacterium and Veillonella and a significant decrease in Fusobacterium in the oral microbiota compared with the HCs. Immunological biomarker analysis showed elevated levels of inflammatory cytokines (IL-1ß, IFN-γ, TNF-α, IL-8) and immunoglobulin A in the saliva of patients with AILD. The relative abundance of Veillonella was positively correlated with the levels of IL-1ß, IL-8 and immunoglobulin A in saliva and the relative abundance of Lactobacillales in feces. Dysbiosis of the oral microbiota is associated with inflammatory responses and reflects changes in the gut microbiota of patients with AILD. Dysbiosis may play an important role in the pathogenesis of AILD.


Subject(s)
Dysbiosis/immunology , Hepatitis, Autoimmune/immunology , Liver Cirrhosis, Biliary/immunology , Microbiota/immunology , Mouth/microbiology , Aged , Case-Control Studies , Dysbiosis/diagnosis , Dysbiosis/pathology , Eubacterium/growth & development , Eubacterium/immunology , Eubacterium/isolation & purification , Feces/microbiology , Female , Fusobacterium/growth & development , Fusobacterium/immunology , Fusobacterium/isolation & purification , Gene Expression , Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/pathology , Humans , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-1beta/genetics , Interleukin-1beta/immunology , Interleukin-8/genetics , Interleukin-8/immunology , Lactobacillales/growth & development , Lactobacillales/immunology , Lactobacillales/isolation & purification , Liver Cirrhosis, Biliary/diagnosis , Liver Cirrhosis, Biliary/pathology , Male , Middle Aged , Saliva/microbiology , Streptococcus/growth & development , Streptococcus/immunology , Streptococcus/isolation & purification , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology , Veillonella/growth & development , Veillonella/immunology , Veillonella/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL